Trial
NCT01222078
Investigating Re-Dosing With Otelixizumab in Adults With Newly-Diagnosed Type 1 Diabetes Mellitus
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
GlaxoSmithKline
Collaborators
—
Condition
Diabetes Mellitus, Type 1
Intervention
otelixizumab
Why stopped
A Phase 3 study recently reported and demonstrated that the dose of otelixizumab in OTX113390 is not effective.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-10-30